NOT-TR-21-011 Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.

NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:

  • PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)

NCATS expects to issue 2-9 awards (anticipated to be $30,000 to $60,000 Direct Costs) for provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data.